Company

SUMGEN

Hangzhou-based SUMGEN, founded in 2015, develops and commercializes antibody therapeutics for cancer and other serious diseases.

About

Founded in 2015 and based in Hangzhou, China, Hangzhou Sumgen Biotech Co., Ltd., trading as SUMGEN, is a biopharmaceutical company focused on antibody therapeutics for cancer and other serious diseases. Its pipeline centers on immuno-oncology targets, with SG001, SG301, SG404 and SG12473 in clinical study. The company closed Series C funding in December 2025 from Oriental Fortune Capital and Chime Biologics Limited Qijian Foundation.

4Funding rounds

10Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in